Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last901 to 920 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| E-MOTIVE Intervention vs Usual Care: Number of Women Receiving Uterine Massage for PPH | 5,794 of 5,921 4,119 of 4,899 | 13.8 points 12.7 to 14.9 | 10,820 | NCT04341662 A Clinical Trial to Study the Effectiveness of a Care Bundle to Prevent Bleeding After a Woman Has Given Birth |
| ACP Educator Led, Video Assisted Discussion vs Usual Care: Identification of a Goals of Care Conversation in the Electronic Health Record (EHR) During the Index Hospitalization | 3,744 of 6,023 2,396 of 4,779 | 12.0 points 10.1 to 13.9 | 10,802 | NCT04857060 Palliative Care Educator |
| Intervention Arm vs Placebo Arm: Maternal Outcome 6 - Change in Maternal Hemoglobin | 290 of 5,393 333 of 5,398 | -0.8 points -1.7 to 0.1 | 10,791 | NCT02409680 Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN) |
| LNG IUD vs Cu-IUD: Breast Cancer Risk | 1,076 of 5,346 1,068 of 5,428 | 0.5 points -1.1 to 2.0 | 10,774 | NCT00461253 Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs |
| LNG IUD vs Cu-IUD: serious adverse events | 1,085 of 5,346 1,130 of 5,428 | -0.5 points -2.0 to 1.0 | 10,774 | NCT00461253 Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs |
| Open Group vs Masked Group: Number of Infants With Umbilical-artery Blood pH < = 7.05 and Base Deficit in Extracellular Fluid > = 12 mmol/Liter (Primary Outcome Component) | 3 of 5,362 8 of 5,359 | -0.1 points -0.2 to 0.0 | 10,721 | NCT01131260 Fetal ST Segment and T Wave Analysis in Labor |
| TICAGRELOR vs PLACEBO: Number of Participants With Modified Rankin Scale (mRS) Score >1 at Visit 3 | 1,282 of 5,386 1,284 of 5,333 | -0.3 points -1.9 to 1.3 | 10,719 | NCT03354429 THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death |
| Intervention vs Control Group: Number of Patients Enrolled | 5,546 of 5,546 5,098 of 5,098 | 0.0 points -0.1 to 0.1 | 10,644 | NCT03044158 GeneXpert Performance Evaluation for Linkage to Tuberculosis Care |
| Intervention vs Control Group: Number Diagnosed With Microbiologically-confirmed TB | 389 of 5,546 299 of 5,098 | 1.1 points 0.2 to 2.1 | 10,644 | NCT03044158 GeneXpert Performance Evaluation for Linkage to Tuberculosis Care |
| Intervention vs Control Group: Number Treated for TB | 485 of 5,546 339 of 5,098 | 2.1 points 1.1 to 3.1 | 10,644 | NCT03044158 GeneXpert Performance Evaluation for Linkage to Tuberculosis Care |
| Intervention vs Control Group: Number Treated for Microbiologically-confirmed TB Within 14 Days After Presentation to the Health Center for TB Evaluation | 342 of 5,546 220 of 5,098 | 1.9 points 1.0 to 2.7 | 10,644 | NCT03044158 GeneXpert Performance Evaluation for Linkage to Tuberculosis Care |
| Intervention vs Control Group: Number Diagnosed AND Treated for TB | 362 of 5,546 199 of 5,098 | 2.6 points 1.8 to 3.5 | 10,644 | NCT03044158 GeneXpert Performance Evaluation for Linkage to Tuberculosis Care |
| Intervention vs Control Group: Number Diagnosed and Treated for Microbiologically-confirmed TB | 251 of 5,546 106 of 5,098 | 2.4 points 1.8 to 3.1 | 10,644 | NCT03044158 GeneXpert Performance Evaluation for Linkage to Tuberculosis Care |
| Intervention vs Control Group: Number Tested for TB According to National Guidelines | 5,108 of 5,546 2,687 of 5,098 | 39.4 points 37.8 to 40.9 | 10,644 | NCT03044158 GeneXpert Performance Evaluation for Linkage to Tuberculosis Care |
| aQIV (≥6 to <72 Months) vs TIV/QIV (≥6 to <72 Months): deaths from any cause | 1 of 5,339 3 of 5,272 | -0.0 points -0.1 to 0.1 | 10,611 | NCT01964989 Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children. |
| Sotagliflozin vs Placebo: deaths from any cause | 246 of 5,292 246 of 5,292 | 0.0 points -0.8 to 0.8 | 10,584 | NCT03315143 Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk |
| Sotagliflozin vs Placebo: serious adverse events | 1,236 of 5,291 1,331 of 5,286 | -1.8 points -3.5 to -0.2 | 10,577 | NCT03315143 Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk |
| Bococizumab (PF-04950615) vs Placebo: deaths from any cause | 54 of 5,276 61 of 5,279 | -0.1 points -0.5 to 0.3 | 10,555 | NCT01975389 The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects |
| Bococizumab (PF-04950615) vs Placebo: serious adverse events | 934 of 5,276 994 of 5,279 | -1.1 points -2.6 to 0.3 | 10,555 | NCT01975389 The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects |
| Pemafibrate vs Placebo: deaths from any cause | 308 of 5,264 310 of 5,274 | -0.0 points -0.9 to 0.9 | 10,538 | NCT03071692 Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=46
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT04341662-d92cacf0",
"title": "E-MOTIVE Intervention vs Usual Care: Number of Women Receiving Uterine Massage for PPH",
"summary": "5794 of 5921 against 4119 of 4899; risk difference 13.8 points, 95% interval 12.7 to 14.9; NCT04341662, A Clinical Trial to Study the Effectiveness of a Care Bundle to Prevent Bleeding After a Woman Has Given Birth",
"record": "/library/comparisons/NCT04341662-d92cacf0",
"nct_id": "NCT04341662",
"kind": "outcome",
"participants": 10820,
"risk_difference": {
"value": 0.13776708701723128,
"lower": 0.12701271407868714,
"upper": 0.1488126257845656
},
"group_1": "5,794 of 5,921",
"group_2": "4,119 of 4,899",
"difference": "13.8 points",
"interval": "12.7 to 14.9",
"trial_title": "A Clinical Trial to Study the Effectiveness of a Care Bundle to Prevent Bleeding After a Woman Has Given Birth"
},
{
"id": "NCT04857060-7df5f7c5",
"title": "ACP Educator Led, Video Assisted Discussion vs Usual Care: Identification of a Goals of Care Conversation in the Electronic Health Record (EHR) During the Index Hospitalization",
"summary": "3744 of 6023 against 2396 of 4779; risk difference 12.0 points, 95% interval 10.1 to 13.9; NCT04857060, Palliative Care Educator",
"record": "/library/comparisons/NCT04857060-7df5f7c5",
"nct_id": "NCT04857060",
"kind": "outcome",
"participants": 10802,
"risk_difference": {
"value": 0.12025701713911974,
"lower": 0.10147958126311983,
"upper": 0.13893474100461248
},
"group_1": "3,744 of 6,023",
"group_2": "2,396 of 4,779",
"difference": "12.0 points",
"interval": "10.1 to 13.9",
"trial_title": "Palliative Care Educator"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=47",
"request_id": "9rZHAFhO4wMj8qg_"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant